Related Experiment Video
Updated: Jun 10, 2026

Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
Published on: March 23, 2016
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational,
Istvan Bitter1, Tamás Treuer, Nesrin Dilbaz
1Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
Objectives:
The aim of this study was to compare patients' preference for olanzapine orodispersible tablet (ODT) with oral conventional tablet (OCT).
Methods:
A 12-week randomized, crossover, multinational, open-label study was conducted to estimate the proportion of patients preferring ODT or OCT. Outpatients with stable schizophrenia on OCT monotherapy were randomly assigned 1:1 to ODT or OCT. Compliance and drug attitude were measured using the Drug Attitude Inventory (DAI-10) and Medication Adherence Form (MAF) scales; tolerability and safety by Association for Methodology and Documentation in Psychiatry (AMDP-5) questionnaire and adverse event summary.
Results:
A total of 175 patients answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence); 21 (12%) expressed no preference. There was no significant change in DAI-10 with either formulation. MAF was above 75% in 94% vs. 93% of patients on ODC and OCT, respectively. Compliance as measured by tablet count was above 98% on both formulations. The adverse event profiles did not differ between formulations. Mean weight increase over 6 weeks on ODT was 0.8 kg and on OCT was 0.6 kg.
Conclusions:
Given the importance of patients' preference for treatment planning and success, the ODT formulation should be routinely considered as a treatment option.
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Drug Delivery Systems: Different Types
Oral Drug Delivery Systems: Introduction
Antipsychotic Drugs: Typical and Atypical Agents
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies